FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
about
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersFirst-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy
P2860
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@en
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@nl
type
label
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@en
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@nl
prefLabel
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@en
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@nl
P1433
P1476
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
@en
P2093
Sebastian Stintzing
Volker Heinemann
P304
P356
10.1016/S1470-2045(14)71036-8
P577
2014-11-24T00:00:00Z